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RESUMEN
Se han diseñado y sintetizado una serie de compuestos 
nuevos de diselenuro de diquinazolina con 4-cloroquina-
zolina y diselenuro de sodio. Sus estructuras se han con-
firmado mediante IR, 1H NMR, 13C NMR, y análisis elemen-
tales. La actividad antitumoral de los nuevos compuestos 
se evaluaba con el método MTT.  Los compuestos 1a, 
1c, 1h y 1i mostraban actividad contra las células MDA-
MB-435, A549, MDA-MB-231, SiHa, y HeLa. Además, en 
comparación con los fármacos anticancerígenos comer-
ciales Gefitinib, Oxaliplatino, Taxol, 10-Hidroxi camptote-
cina y clorhidrato de Epirubicina,  el producto 1a ejercía 
mejores efectos antitumorales en las correspondientes 
líneas celulares en una concentración 10 μM. 
Palabras clave: Quinazolina; diselenuro de diquinazolina; 
síntesis; actividades anticancerígenas; método MTT.
SUMMARY
A series of novel diquinazoline diselenide compounds 
was designed and synthesized with substituted 4-chloro-
quinazoline and sodium diselenide. Their structures were 
confirmed by IR, 1H NMR, 13C NMR, and elemental anal-
yses. The antitumor activity of the new compounds was 
evaluated by MTT method. Compound 1a, 1c, 1h and 1i 
were found to have activities against MDA-MB-435, A549, 
MDA-MB-231, SiHa, and HeLa cells. Moreover, compared 
with the commercial anticancer drugs Gefitinib, Oxalipla-
tin, Taxol, 10-Hydroxycamptothecin, and Epirubicin Hy-
drochloride, 1a exerted better antitumor effects on corre-
sponding cell lines at 10 μM. 
Keywords: Quinazoline; diquinazoline diselenide; synthe-
sis; anticancer activities; MTT method.
RESUM
S’han dissenyat i sintetitzat una sèrie de compostos nous 
de diselenuro de diquinazolina amb 4-cloroquinazolina 
i diselenuro de sodi. S’han confirmat les seves estructu-
res mitjançant IR, 1H NMR, 13C NMR, i anàlisis elemen-
tals. L’activitat antitumoral dels nous compostos s’ava-
luava amb el mètode MTT.  Els compostos 1a, 1c, 1h y 
1i mostraven activitat contra les cèl·lules MDA-MB-435, 
A549, MDA-MB-231, SiHa, i HeLa. A més, en compara-
ció amb els fàrmacs anticancerígens comercials Gefitinib, 
Oxaliplatino, Taxol, 10-Hidroxi camptotecina i clorhidrat de 
Epirubicina,  el producte 1a exercia millors efectes antitu-
morals en les corresponents línies cel·lulars en una con-
centració 10 μM. 
Paraules clau: Quinazolina; diselenuro de diquinazolina; 
síntesi; activitats anticancerígens; mètode MTT.
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INTRODUCTION
Quinazoline compounds are a series of small-molecule 
drugs with good EGFR inhibition activity.1 Some examples 
are Iressa (ZD 1839), Tarceva (OSI-774), Gleevec (STI571), 
and CI-1033. Selenide compounds especially heterocy-
clic containing-selenium compounds exert multi-targeted 
anticancer effects through various mechanisms.2,3 Some 
selenide drugs that are currently undergoing clinical stud-
ies include Ebselen4, which has anti-inflammatory and 
antioxidant properties, and Selenazofurin5, which has an-
tiviral and antitumor properties. As part of our ongoing re-
search on heterocyclic compounds, we were particularly 
interested in 4-substituted quinazolines from O, N and S 
atom6-8. Their activities are found to vary, but anticancer 
activity is not significantly reduced. According to bio-elec-
tronic line principle, we design and synthesize a series of 
novel diquinazoline diselenide compounds considering the 
multi-mechanism and multi-targeting anticancer effects of 
organoselenium compounds, together with the good in-
hibitory activity of EGFR quinazoline compounds. In this 
paper, a series of diquinazoline diselenide compounds 
was prepared with substituted 4-chloroquinazoline and 
sodium diselenide (Figure 1). The structures of the new 
compounds were confirmed by elemental analysis, IR, 1H 
NMR, and 13C NMR. The antitumor activities of the new 
compounds were also evaluated by MTT method. Among 
them, 1a, 1c, 1h and 1i showed good activities against 
MDA-MB-435, A549, MDA-MB-231, SiHa, and HeLa cells. 
The inhibition activity of 1a against MDA-MB-435, A549, 
MDA-MB-231, SiHa, and HeLa cells was 99.7%, 81.6%, 
93.1%, 90.6%, and 94.2% at 10 μM concentration. 
RESULTS AND DISCUSSION
The synthesis of intermediates 3a, 3b, 3c, 3d, 3h and 3i 
from anthranilic acid or substituted anthranilic acid react-
ed with formamide. The synthesis of intermediates 3e and 
3j from anthranilic acid (2a) or substituted anthranilic acid 
reacted with urea. The synthesis of intermediate 3f from 
anthranilic acid reacted with acetic anhydride, and then 
reacted with ammonium acetate. The synthesis of inter-
mediates 3g needs three steps from 2a. Firstly anthranilic 
acid reacted with benzoyl chloride, and then reacted with 
aqua ammonia, finally reacted with sodium hydroxide. In 
chlorination step, synthesis of 4e, 4g and 4j must needed 
phosphorus oxychloride catalyzing by dimethylformamide. 
The others intermediates needed thionyl chloride catalyz-
ing by dimethylformamide. R1-R3 expresses atom or radi-
cal see in Table 1.
Unfortunately, the yields of the synthesis of diselenide 
compounds were not ideal below in 50%. Some products 
were insoluble in ethanol during the reaction. It’s as a by-
product after the analysis, most probably were quinazoline 
diselenide sodium compounds. Based on literature9, the 
yields of synthesis of dibenzyl diselenides by using ben-
zyl chloride or benzyl bromide as starting materials were 
very good. But using 4-chloroquinazoline compounds as 
starting materials, the yields of synthesis of diquinazoline 
diselenide compounds were not achieve the desired goals. 
The yields remained low changing the reaction conditions, 
which itself quinazoline ring large size had an important 
effect. The novel diquinazoline diselenide compounds 
were the symmetrical structure of compounds. Based on 
analysis of 1H NMR and 13C NMR spectrogram, H and C 
chemical shift had the same position in both quinazoline 
groups. 
MDA-MB-435, A549, MDA-MB-231, SiHa, and HeLa cell 
lines were used for anticancer drug discovery screening 
through MTT assay. Table 2 showed that after 72 h of 
treatment, 1a, 1b, 1d, 1f, and 1h showed considerable an-
ticancer activities for the above cell lines at 10 μM and 
even at 1 μM in vitro compared with the DMSO negative 
control. Furthermore, compared with the commercial an-
ticancer drugs Gefitinib (a small molecular-targeted anti-
cancer drug), Oxaliplatin (a traditional chemotherapeutic 
drug), Taxol (a traditional chemotherapeutic drug), 10-Hy-
droxycamptothecin (one kind of plant anticancer drug), 
and Epirubicin Hydrochloride (an antibiotics anticancer 
drug), 1a showed better antitumor effects on correspon-
ding cell lines at 10 μM (Table 2). These result suggested 
that 1a was a potential antitumor agent. 
Figure 1 Synthesis of diquinazolin-4-yl diselenide compounds
1
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Figure 1 Synthesis of diquinazolin-4-yl diselenide compounds. 
Table 1 atom or radical of R1, R2 and R3
Substituent 
Group
Title compound 1a-1j and Intermediates 4a-4j
1a, 4a 1b, 4b 1c, 4c 1d, 4d 1e, 4e 1f, 4f 1g, 4g 1h, 4h 1i, 4i 1j, 4j
R1 H 6-Cl 6-Br 6-I H H H 6,8-2Cl 6,8-2Br 6-Cl




3a 3b 3c 3d 3e 3f 3g 3h 3i 3j




2a 2b 2c 2d 2e 2f
R1 H 6-Cl 6-Br 6-I 6,8-2Cl 6,8-2Br
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1 μM 10 μM 1μM 10μM 1 μM 10μM
1a -0.16 ±1.59 99.69±0.18* 5.54 ±2.38 81.64 ±2.90* 5.27 ±3.25 93.11 ±1.58*
1b 6.32 ±5.95 51.1 ±3.21* -20.92±4.68* 20.07 ±6.00* 4.32 ±6.95 16.9 ±5.33*
1c -1.41 ±2.68 63.67±1.23* -36.78 ±5.68* 28.66 ±1.52* -19.91±11.71* 34.46±23.88*
1d -0.22 ±3.25 42.3 ±4.56* -7.68 ±5.10 38.37 ±3.51* -6.18 ±6.29 7.60 ±2.89
1e -0.22 ±3.25 4.23 ±4.56 -5.16 ±4.67 10.82 ±4.90 -29.33 ±14.31* -7.56 ±6.47
1f -10.83±3.87 3.40 ±2.59 -6.35 ±4.38 45.66 ±1.92* -6.34 ±7.02 4.01 ±1.96
1g 4.73 ±5.29 3.12 ±6.96 3.44 ±2.71 16.15 ±3.23* -3.67 ±5.25 8.21 ±2.61
1h 9.93 ±4.56 59.07±3.95* 27.77 ±2.06* 34.4 ±2.03* -12.75 ±7.72* 15.94 ±5.06*
1i -1.83 ±3.87 43.4 ±2.59* 2.71 ±6.14 17.86 ±5.68* -1.89 ±6.48 -4.44 ±3.97
1j 6.32 ±5.95 -1.10 ±3.21 10.02 ±3.99 -4.61 ±3.50 10.35 ±3.69* 11.4 ±1.07*
Oxaliplatin 14.36±2.90* 48.73±4.76* 16.48 ±3.46* 39.76 ±2.71* 10.22 ±6.75 45.39 ±0.12*
Gefitinib 10.98 ±7.59 70.48±5.23* -6.04 ±9.53 83.3 ±9.53* 9.73 ±8.04 67.52 ±4.14*
10-Hydroxy 
camptothecin
95.49±1.13* 99.15±0.20* 60.98 ±1.62* 77.94 ±1.19* NTa NTa
Taxol 95.6 ±0.75* 92.32±1.65* 88.35 ±0.92* 100 ±0.68* NTa NTa
Epirubicin 
Hydrochloride




1μM 10μM 1μM 10μM
1a 27.82 ±6.56* 90.57 ±5.73* 23.13 ±2.07 94.24 ±2.10*
1b 5.45 ±1.16 34.06 ±8.77* 5.15 ±5.46 28.67 ±6.52*
1c 40.66 ±5.42* 68.58 ±7.98* 1.55 ±4.80 17.15 ±7.74
1d 9.38 ±1.28* 22.59 ±1.89* -23.41 ±9.56 8.40 ±6.69
1e 7.50 ±3.49 21.15 ±3.87* 2.86 ±6.72 12.84 ±4.38
1f 5.45 ±1.16 34.06 ±8.77* -11.37 ±5.36 0.34 ±5.13
1g 7.5 ±3.49 21.15 ±3.87* -0.54 ±2.99 -2.38 ±3.85
1h 19.34 ±3.96* 23.26 ±4.78* 5.86 ±4.07 18.14 ±3.22
1i 20.55 ±8.94* 36.92 ±6.12* -20.59 ±8.57 0
1j 15.72 ±11.41 64.45 ±7.44* 2.49 ±7.37 -18.35 ±7.24
Oxaliplatin 34.22 ±5.56* 50.86 ±6.66* -0.45 ±6.35 35.63 ±4.71*
Gefitinib NTa NTa NTa NTa
10-Hydroxy camptothecin 37.39 ±2.39* 75.31 ±0.35* NTa NTa
Taxol 77.54 ±1.90* 99.08 ±0.20* NTa NTa
Epirubicin Hydrochloride 73.14 ±8.16* 99.77 ±0.37* NTa NTa
*Compared with DMSO control, compound 1a-1j, Gefitinib or Oxaliplatin treatment of 72 h showed statistically significant 
inhibition (P<0.05) against cell growth. 
a NT mean not tested.
EXPERIMENTAL SECTION 
All melting points of the products were determined on a 
MP120 digital melting point tester (Jinan Haineng Instru-
ments, Ltd. Co., China) and are not corrected. The infrared 
spectra were recorded on a MAGANA-IR550(series II)spec-
trometer in KBr disks. 1H and 13C-NMR spectra were recor-
ded on a spectrometer BRUKER AVANCE III 600 MHz (600 
and 150 MHz respectively) at room temperature in DMSO-
d6 using TMS as internal standard. Elemental analysis was 
performed by an Elementar Vario EL III CHN analyzer. The 
mass spectra were taken on a Agilent 6210 spectrometer.
The following compounds were prepared as described in
the literature. 4-chloroquinazoline (4a): white needle crys-
tal, yield 54.5%, mp 94-95 °C (mp 96.5-97.5 °C10); 4,6-di-
chloroquinazoline (4b): white solid, yield 62.5%, mp 152-
154 °C (mp 154-155 °C11); 6-bromo-4-chloroquinazoline 
(4c): yellowish solid, yield 34.2%, mp 162-164 °C (mp 164-
166 °C12); 4-chloro-6-iodoquinazoline (4d): orange-yellow 
solid, yield 33.1%, mp 188-191 °C (mp 193-195°C13); 
2,4-dichloro quinazoline (4e): yield 80.2%, mp 118-121 
oC (mp 119.5 oC14); 4-chloro-2-methylquinazoline (4f): 
yield 18.5%, mp 98.9-101.3 oC (mp 86-88 oC15); 4-chloro-
2-phenylquinazoline (4g):  yellowish solid, yield 87.3%, 
mp 127.0-128.0 °C (mp 124 °C16); 4,6,8-trichloroquinazo-
line (4h): yellowwish solid, yield 15.3%, mp 145.5-147.5 
°C (mp 139-140 °C17); 6,8-dibromo-4-chloroquinazoline 
(4i): orange-yellow solid, yield 66.8%, mp 159.0-159.3 °C 
(mp 189-190 °C13); 2,4,6-trichloroquinazoline (4j): yellow-
wish solid, yield 75.5%, mp 121-124 °C (mp 131 °C18). All 
the other reagents used in the experiment were analytical 
reagents without any modification.
General procedure for preparation diquinazolin-4-yl disel-
enide compounds 1a-1j
4-Chloroquinazoline or substituted 4-chloroquinazoline 
(5.0 mmol) was added to an ethanolic sodium diselenide 
solution 0.51 g (2.5 mmol) in 1 h. The solution was heat-
ed with reflux for 8–24 h, and reaction completion was 
monitored by TLC. After cooling and acidification using 
glacial acetic acid (pH 5), the solvents were removed in 
vacuo and recrystallized from DMF-H2O to give the de-
sired products 1a–1j.
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1,2-bis(quinazolin-4-yl)diselane (1a): orange-red solid, 
yield 44.2%, mp 220.7-222.0 ºC. IR spectrum (thin layer), 
n, cm-1: 3140.8, 3055.6 (Ar-H), 1617.2-1466.4 (quinazoline 
skeleton). 1H NMR spectrum (600 MHz, DMSO-d6), δ, ppm 
(J, Hz): 7.66 (2H, s, H-2, 2’ Ar), 7.76 (2H, d, J = 8.4, H-8, 
8’ Ar), 7.99 (2H, d, J = 8.4, H-5, 5’ Ar), 8.21 (2H, t, J = 
7.8, H-6, 6’ Ar), 8.61 (2H, t, J = 7.8, H-7, 7’ Ar). 13C NMR 
spectrum (150 MHz, DMSO-d6), δ, ppm (J, Hz): 127.6 (2C, 
C-5, 5’ Ar), 129.5 (2C, C-6, 6’ Ar), 132.4 (2C, C-8, 8’ Ar), 
136.3 (2C, C-7, 7’ Ar), 143.9 (2C, C-10, 10’ Ar), 144.7 (2C, 
C-9, 9’ Ar), 154.2 (2C, C-2, 2’ Ar), 162.8 (2C, C-4, 4’ Ar). 
Mass spectrum (EI, 70 eV), m/z (Irel, %): 420.0 [M+2]
+ (56), 
417.9 [M]+ (48), 327.7 [M-C6H4N]
+ (100), 301.7 [M-C6H4N-
CN]+ (33), 274.8 [M-C6H4N-2CN]
+ (88), 207.4 [M-H-C8H5N-
2Se]
+ (80), 120.2 [M-C8H5N2Se-C6H4N]
+ (22). Anal. calcd for 
C16H10N4Se2: C 46.17, H 2.42, N 13.46; found C 46.42, H 
2.53, N 13.31.
1,2-bis(6-chloroquinazolin-4-yl)diselane (1b): orange-
-red solid, yield 29.0%, mp 255.2-257.9 ºC. IR spectrum 
(thin layer), n, cm-1: 3083.3 (Ar-H), 1615.4-1450.9 (qui-
nazoline skeleton), 647.7 (C-Cl). 1H NMR spectrum (600 
MHz, DMSO-d6), δ, ppm (J, Hz): 7.78 (2H, d, J = 8.4, H-7, 
7’ Ar), 8.00 (2H, d, J = 8.4, H-8, 8’ Ar), 8.20 (2H, s, H-5, 
5’ Ar), 8.55 (2H, s, H-2, 2’ Ar). 13C NMR spectrum (150 
MHz, DMSO-d6), δ, ppm (J, Hz): 130.9 (2C, C-5, 5’ Ar), 
131.3 (2C, C-10, 10’ Ar), 133.6 (2C, C-8, 8’ Ar), 133.9 (2C, 
C-7, 7’ Ar), 136.1 (2C, C-6, 6’ Ar), 142.6 (2C, C-9, 9’ Ar), 
145.2 (2C, C-2, 2’ Ar), 186.9 (2C, C-4, 4’ Ar). Anal. cal-
cd for C16H8Cl2N4Se2: C 39.62, H 1.66, N 11.55; found C 
39.50, H 1.45, N 11.38.
1,2-bis(6-bromoquinazolin-4-yl)diselane (1c): oran-
ge-red solid, yield 40.8%, mp 225.9-227.3 ºC. IR spec-
trum (thin layer), n, cm-1: 3017.6 (Ar-H), 1617.4-1454.8 
(quinazoline skeleton), 559.1 (C-Br). 1H NMR spectrum 
(600 MHz, DMSO-d6), δ, ppm (J, Hz): 7.71 (2H, d, J = 9.0, 
H-8, 8’ Ar), 8.12 (2H, dd, J7,8 = 9.0, J5,7 = 1.8, H-7, 7’ Ar), 
8.22 (2H, s, H-2, 2’ Ar), 8.71 (2H, d, J = 1.8, H-5, 5’ Ar). 
13C NMR spectrum (150 MHz, DMSO-d6), δ, ppm (J, Hz): 
122.4 (2C, C-6, 6’ Ar), 131.4 (2C, C-10, 10’ Ar), 133.9 (2C, 
C-5, 5’ Ar), 134.1 (2C, C-8, 8’ Ar), 138.8 (2C, C-7, 7’ Ar), 
142.9 (2C, C-9, 9’ Ar), 145.3 (2C, C-2, 2’ Ar), 186.5 (2C, 
C-4, 4’ Ar). Anal. calcd for C16H8Br2N4Se2: C 33.48, H 1.40, 
N 9.76; found C 33.25, H 1.28, N 9.98.
1,2-bis(6-iodoquinazolin-4-yl)diselane (1d): orange-red 
solid, yield 29.3%, mp 225.9-227.3 ºC. IR spectrum (thin 
layer), n, cm-1: 3013.1 (Ar-H), 1615.7-1450.7 (quinazoline 
skeleton), 490.0 (C-I). 1H NMR spectrum (600 MHz, DM-
SO-d6), δ, ppm (J, Hz): 7.53 (2H, d, J = 8.4, H-8, 8’ Ar), 8.20 
(2H, s, H-5, 5’ Ar), 8.25 (2H, d, J = 7.8, H-7, 7’ Ar), 8.91 
(2H, s, H-2, 2’ Ar). 13C NMR spectrum (150 MHz, DMSO-
-d6), δ, ppm (J, Hz): 95.6 (2C, C-6, 6’ Ar), 131.0 (2C, C-10, 
10’ Ar), 134.2 (2C, C-5, 5’ Ar), 140.4 (2C, C-8, 8’ Ar), 143.2 
(2C, C-7, 7’ Ar), 144.3 (2C, C-9, 9’ Ar), 145.3 (2C, C-2, 2’ 
Ar), 186.5 (2C, C-4, 4’ Ar). Anal. calcd for C16H8I2N4Se2: C 
28.77, H 1.21, N 8.39; found C 28.64, H 1.09, N 8.55.
1,2-bis(2-chloroquinazolin-4-yl)diselane (1e): yellow-
-green solid, yield 9.5%, mp 134.2-136.0 ºC. IR spectrum 
(thin layer), n, cm-1: 3079.0 (Ar-H), 1682.2-1469.2 (quina-
zoline skeleton). 1H NMR spectrum (600 MHz, DMSO-d6), 
δ, ppm (J, Hz): 7.18 (2H, t, J =7.8, H-6, 6’ Ar), 7.38 (2H, t, 
J = 7.8, H-7, 7’ Ar), 7.46 (2H, d, J =7.8, H-5, 5’ Ar), 7.89 
(2H, d, J = 7.8, H-8, 8’ Ar). 13C NMR spectrum (150 MHz, 
DMSO-d6), δ, ppm (J, Hz): 114.8 (2C, C-10, 10’ Ar), 116.6 
(2C, C-5, 5’ Ar), 122.8 (2C, H-8, 8’ Ar), 127.3 (2C, C-6, 6’ 
Ar), 135.4 (2C, C-7, 7’ Ar), 141.0 (2C, H-9, 9’ Ar), 159.3 
(2C, C-2, 2’ Ar), 172.5 (2C, C-4, 4’ Ar). Anal. calcd for 
C16H8Cl2N4Se2: C 39.62, H 1.66, N 11.55; found C 39.66, 
H 1.51, N 11.44.
1,2-bis(2-methylquinazolin-4-yl)diselane (1f): nacarat 
solid, yield 6.3%, mp 135.4-137.5 ºC. IR spectrum (thin 
layer), n, cm-1: 3074.7 (Ar-H), 2924.7 (nasCH3), 2854.8 (nsCH3), 
1684.2-1468.1 (quinazoline skeleton). 1H NMR spectrum 
(600 MHz, DMSO-d6), δ, ppm (J, Hz): 3.34 (6H, s, 2CH3), 
7.65 (2H, t, J =7.8, H-6, 6’ Ar), 7.84 (2H, d, J =7.8, H-5, 
5’ Ar), 7.89 (2H, t, J =7.8, H-7, 7’ Ar), 8.19 (2H, d, J =7.8, 
H-8, 8’ Ar). 13C NMR spectrum (150 MHz, DMSO-d6), δ, 
ppm (J, Hz): 24.8 (2C, 2CH3), 123.4 (2C, C-10, 10’ Ar), 
126.5 (2C, C-5, 5’ Ar), 128.9 (2C, C-6, 6’ Ar), 129.1 (2C, 
C-8, 8’ Ar), 135.3 (2C, C-7, 7’ Ar), 147.7 (2C, C-9, 9’ Ar), 
160.6 (2C, C-4, 4’ Ar), 161.4 (2C, C-2, 2’ Ar). Anal. calcd 
for C18H14N4Se2: C 48.66, H 3.18, N 12.61; found C 48.38, 
H 2.95, N 12.48.
1,2-bis(2-phenylquinazolin-4-yl)diselane (1g): orange 
solid, yield 11.6%, mp 235.1-238.1 ºC. IR spectrum (thin 
layer), n, cm-1: 3066.7 (Ar-H), 1631.9-1455.4 (quinazoline 
skeleton). 1H NMR spectrum (600 MHz, DMSO-d6), δ, ppm 
(J, Hz): 7.52-7.61 (8H, m, H-3, 3’, 4, 4’, 5, 5’ Ph + H-6, 6’ 
quinazoline), 7.75 (2H, d, J = 8.4, H-5, 5’ Ar), 7.85 (2H, 
t, J = 8.4, H-7,7’ Ar), 8.17-8.21 (6H, m, H-8, 8’ quinazo-
line + H-2, 2’, 6, 6’ Ph). 13C NMR spectrum (150 MHz, 
DMSO-d6), δ, ppm (J, Hz): 121.5 (2C, C-10, 10’ Ar), 126.3 
(2C, C-5, 5’ Ar), 127.1 (2C, C-6, 6’ Ar), 128.0 (2C, C-8, 8’ 
Ar), 128.2 (2C, C-4, 4’ Ph), 129.1 (4C, C-2, 2’, 6, 6’ Ph), 
131.8 (4C, C-3, 3’, 5, 5’ Ph), 133.2 (2C, C-7, 7’ Ar), 135.1 
(2C, C-1, 1’ Ph), 149.2 (2C, C-9, 9’ Ar), 152.8 (2C, C-4, 4’ 
Ar), 162.7 (2C, C-2, 2’ Ar). Anal. calcd for C28H18N4Se2: C 
59.17, H 3.19, N 9.86; found C 59.38, H 2.99, N 9.73.
1,2-bis(6,8-dichloroquinazolin-4-yl)diselane (1h): oran-
ge solid, yield 30.5%, mp 261.5-263.8 ºC. IR spectrum 
(thin layer), n, cm-1: 3082.9 (Ar-H), 1607.9-1470.9 (qui-
nazoline skeleton), 656.6 (C-Cl). 1H NMR spectrum (600 
MHz, DMSO-d6), δ, ppm (J, Hz): 8.10 (2H, s, H-5, 5’ Ar), 
8.27 (2H, s, H-7, 7’ Ar), 8.90 (2H, s, H-2, 2’ Ar). 13C NMR 
spectrum (150 MHz, DMSO-d6), δ, ppm (J, Hz): 118.1 (2C, 
C-5, 5’ Ar), 122.0 (2C, C-10, 10’ Ar), 131.2 (2C, C-7, 7’ Ar), 
133.4 (2C, C-6, 6’ Ar), 134.3 (2C, C-8, 8’ Ar), 155.8 (2C, 
C-9, 9’ Ar), 166.1 (2C, C-2, 2’ Ar), 173.0 (2C, C-4, 4’ Ar). 
Anal. calcd for C16H6Cl4N4Se2: C 34.69, H 1.09, N 10.11; 
found C 34.90, H 0.91, N 10.13.
1,2-bis(6,8-dibromoquinazolin-4-yl)diselane (1i): oran-
ge-red solid, yield 9.5%, mp 124.2-125.3 ºC. IR spectrum 
(thin layer), n, cm-1: 3079.6 (Ar-H), 1600.2-1465.1 (qui-
nazoline skeleton), 632.7 (C-Br). 1H NMR spectrum (600 
MHz, DMSO-d6), δ, ppm (J, Hz): 8.28 (2H, s, H-5, 5’ Ar), 
8.51 (2H, s, H-7, 7’ Ar), 8.92 (2H, s, H-2, 2’ Ar). 13C NMR 
spectrum (150 MHz, DMSO-d6), δ, ppm (J, Hz): 118.5 (2C, 
C-6, 6’ Ar), 120.1 (2C, C-10, 10’ Ar), 124.4 (2C, C-5, 5’ Ar), 
125.8 (2C, C-8, 8’ Ar), 139.9 (2C, C-7, 7’ Ar), 147.4 (2C, 
C-9, 9’ Ar), 155.9 (2C, C-2, 2’ Ar), 165.9 (2C, C-4, 4’ Ar). 
Anal. calcd for C16H6Br4N4Se2: C 26.26, H 0.83, N 7.66; 
found C 26.11, H 0.98, N 7.50.
1,2-bis(2,6-dichloroquinazolin-4-yl)diselane (1j): pale 
yellow solid, yield 18.3 %, mp 133.2-135.5 ºC. IR spec-
trum (thin layer), n, cm-1: 3071.8 (Ar-H), 1694.1-1464.6 
(quinazoline skeleton), 619.4 (C-Cl). 1H NMR spectrum 
(600 MHz, DMSO-d6), δ, ppm (J, Hz): 7.67 (2H, d, J = 8.4, 
H-7, 7’ Ar), 7.78 (2H, d, J =8.4, H-8, 8’ Ar), 7.81 (2H, s, 
H-5, 5’ Ar). 13C NMR spectrum (150 MHz, DMSO-d6), δ, 
ppm (J, Hz): 118.0 (2C, C-10, 10’ Ar), 118.9 (2C, C-5, 5’ 
Ar), 126.4 (2C, C-8, 8’ Ar), 129.4 (2C, C-7, 7’ Ar), 135.9 
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(2C, C-6, 6’ Ar), 150.5 (2C, C-9, 9’ Ar), 162.2 (2C, C-2, 2’ 
Ar), 172.9 (2C, C-4, 4’ Ar). Anal. calcd for C16H6Cl4N4Se2: 
C 34.69, H 1.09, N 10.11; found C 34.52, H 1.11, N 9.89.
MTT assay 19
MDA-MB-435, A549, MDA-MB-231, SiHa, or HeLa cells 
were grown in 96-well plates (3,000 cells per well) and 
maintained in 10 % FBS/RPMI 1640 medium at 37 °C for 
24 h. After cell attachment, the tested cells were treated 
with either DMSO alone as negative control or varying 
concentrations of tested drug. After 72 h of treatments, 
the inhibition effects of title compounds on tested cells 
were measured using an ELISA plate reader (BioTek-Sy-
nergy HT). The experiment was done three times indepen-
dently. As a result, the inhibition rates of title compounds 
against tested tumor cells were measured using the fo-
llowing formula. 
 11
tumor cells were measured using the following formula.  
100%   )
 valuecontrol negative
 valueexperiment -(1  (%) rate Inhibition 
CONCLUSIONS 
A series of diquinazoline diselenide compounds was prepared with substituted 
4-chloroquinazoline and sodium diselenide. Based on all findings, we concluded that 
the title compounds possessed wide-spectrum anticancer activity in MDA-MB-435, 
A549, MDA-MB-231, SiHa, and HeLa cell lines. Furthermore, compared with the 
commercial anticancer drugs Gefitinib, Oxaliplatin, Taxol, 10-Hydroxycamptothecin, 
and Epirubicin Hydrochloride, 1a also exerted better antitumor effects on the 
corresponding cell lines at 10 μM. 
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